OT-007B

OT-007B is a proprietary nasal-mucosa-optimized **steroid cream** developed for **intra-nasal treatment of chronic rhinosinusitis (CRS)**, particularly for patients who have persistent symptoms following endoscopic sinus surgery (ESS). It is formulated for single, in-office application and has demonstrated significant, durable improvements in both patient- and physician-reported CRS symptom scores in a Phase 2 clinical trial. The active ingredient, while not explicit in all trials, is implied to be related to a corticosteroid formulation, aiming to reduce inflammation and maintain sinus patency after surgery. The drug is designed to integrate into ENT clinical practice for hard-to-treat post-surgical CRS cases[4][6][7][9][16].